FDA approves teplizumab: a milestone in type 1 diabetes

New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone. The drug itself, a humanised anti-CD3 monoclonal antibody, delays clinical type 1 diabetes in at-risk individuals and is the first approved disease-modifying drug for type 1 diabetes.